Key Insights

Highlights

Success Rate

91% trial completion (above average)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 37/100

Termination Rate

5.0%

1 terminated out of 20 trials

Success Rate

90.9%

+4.4% vs benchmark

Late-Stage Pipeline

5%

1 trials in Phase 3/4

Results Transparency

50%

5 of 10 completed with results

Key Signals

5 with results91% success

Data Visualizations

Phase Distribution

15Total
Not Applicable (2)
Early P 1 (1)
P 1 (5)
P 2 (6)
P 3 (1)

Trial Status

Completed10
Active Not Recruiting8
Recruiting1
Terminated1

Trial Success Rate

90.9%

Benchmark: 86.5%

Based on 10 completed trials

Clinical Trials (20)

Showing 20 of 20 trials
NCT01552434Phase 1Active Not Recruiting

Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease

NCT04053517Active Not Recruiting

Financial Distress in Advanced Cancer Patients

NCT03525873Phase 3Active Not Recruiting

A Study of Cancer Related Fatigue in Patients With Metastatic Cancer Receiving Anti-PD1 Immunotherapy

NCT03021486Phase 2Active Not Recruiting

Haloperidol With or Without Chlorpromazine in Treating Delirium in Patients With Advanced, Metastatic, or Recurrent Cancer

NCT02491632Phase 2Active Not Recruiting

Physical Activity and Dexamethasone in Reducing Cancer-Related Fatigue in Patients With Advanced Cancer

NCT02152254Phase 2Active Not Recruiting

Initiative for Molecular Profiling and Advanced Cancer Therapy (IMPACT II)

NCT02286687Phase 2Active Not Recruiting

Talazoparib in Treating Patients With Recurrent, Refractory, Advanced, or Metastatic Cancers and Alterations in the BRCA Genes

NCT03743649Phase 2Active Not Recruiting

Haloperidol and Lorazepam in Controlling Symptoms of Persistent Agitated Delirium in Patients With Advanced Cancer Undergoing Palliative Care

NCT01582191Phase 1Completed

Vandetanib and Everolimus in Treating Patients With Advanced or Metastatic Cancer

NCT01790152Recruiting

Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment

NCT03856060Not ApplicableCompleted

Videos and Questionnaires in Assessing Patient Perception of Physician's Compassion, Communication Skills, and Professionalism During Clinic Visits

NCT02595866Phase 1Completed

Testing the Addition of an Experimental Medication MK-3475 (Pembrolizumab) to Usual Anti-Retroviral Medications in Patients With HIV and Cancer

NCT03439085Phase 2Terminated

DNA Plasmid-encoding Interleukin-12/HPV DNA Plasmids Therapeutic Vaccine INO-3112 and Durvalumab in Treating Patients With Recurrent or Metastatic Human Papillomavirus Associated Cancers

NCT04059393Not ApplicableCompleted

PCRC-Supported Legacy Intervention in Pediatric Palliative Care

NCT04089488Completed

Incidence and Prevalence of Cancer in People Living With HIV/AIDS at Cancer Centers in Latin America

NCT04409314Completed

Hypoxia-Specific Imaging to Predict Outcomes of Chimeric Antigen Receptor T-cell Therapy

NCT04186884Completed

Caregiver Burden, Quality of Life, and Symptom Distress at Different Palliative Cancer Care Settings

NCT01624766Phase 1Completed

Everolimus and Anakinra or Denosumab in Treating Participants With Relapsed or Refractory Advanced Cancers

NCT01531361Phase 1Completed

Vemurafenib With Sorafenib Tosylate or Crizotinib in Treating Patients With Advanced Malignancies With BRAF Mutations

NCT02646319Early Phase 1Completed

Nanoparticle Albumin-Bound Rapamycin in Treating Patients With Advanced Cancer With mTOR Mutations

Showing all 20 trials

Research Network

Activity Timeline